Enrollment of Part A completed ahead of schedule and exceeded enrollment target with 123 patients enrolledPart A 16-week proof-of-concept data ...

Apogee begins patient dosing in Part B of phase 2 APEX trial of APG777 to treat moderate-to-severe atopic dermatitis: San Francisco Tuesday, February 4, 2025, 18:00 Hrs [IST] Apog ...

It works on the mechanism of inhibiting IL-4 and IL-13-two dominant cytokines that produce inflammation. By selectively inhibiting these cytokines, Dupixent decreases inflammation ... of 3.15% during ...

According to the lawsuit, Sanofi has failed to provide partner Regeneron adequate information regarding the sales of Dupixent ...

Immunology superstar Dupixent, which first brought Regeneron and Sanofi together in 2007, has entered its megablockbuster era. But even as the billions pile up, Regeneron isn't entirely happy with ...

Below is information on how Dupixent works to treat asthma. How a medication works is also called its mechanism of action. Note: Dupixent should not be used to treat an asthma attack. The ...

Bristol Myers Squibb has continued its ruthless cost-cutting push, dropping plans to commercialize a rival to Dupixent despite meeting its phase 3 goals and pumping the brakes on a would-be ...

Get Instant Summarized Text (Gist) Asthma and antibiotic use at the time of initial endoscopic sinus surgery increase the likelihood of nasal polyp recurrence, necessitating revision surgery. Age ...

and 25% to 30% of them develop nasal polyps as a result. Sanofi and Regeneron have said that CRSwNP has been helping to drive increased sales of Dupixent, which is approved for a range of ...

Despite Eylea's market challenges, Dupixent's strong performance and future potential in COPD, along with a robust pipeline, position Regeneron for recovery in 2025. Regeneron's solid financials ...

The CEO discussed the success of Dupixent and the remarkable achievement ... their excitement about the progress of anti-OX40L mechanism of action. Overall, the positive outcomes from the clinical ...

One primary reason is the strong performance and potential of Dupixent, which is expected to partially counterbalance the uncertainties surrounding Eylea. The expected growth in Dupixent’s ...